Estimation of glomerular filtration rate in cancer patients

Abstract

The frequent need to obtain an estimate of renal function in cancer patients, not least for targeting carboplatin dose, has led to a number of approaches to estimate glomerular filtration rate (GFR). This study aimed to develop a simple and reliable method to estimate GFR using readily-available patient characteristics. Data from 62 patients with estimates of 51Cr-EDTA clearance were analysed to determine the most appropriate formula relating this method of measuring GFR to patient characteristics. The population pharmacokinetics of 51Cr-EDTA were analysed using NONMEM to evaluate the influence of each covariate. The formulae derived were then validated using a further 38 patients and compared with those obtained using existing formulae. 51Cr-EDTA clearance (GFR) was positively related to Dubois surface area, negatively related to age, and inversely related to serum creatinine (SCr). Females had lower 51Cr-EDTA clearance than males. The enzymatic method of SCr assay gave more reliable results than the Jaffe colorimetric method. A measure of creatine kinase significantly improved the estimation of GFR. The new formula produced estimates of GFR which were less biased (Mean Prediction Error = -3%) and more precise (Mean Absolute Prediction Error = 12%) than Cockcroft and Gault (-8% and 16%) or Jelliffe (-15% and 19%) estimates. The formulae developed here can be used to provide reliable estimates of GFR, particularly in regard to targeted dosing of carboplatin.

References 28

1. 1.

   Ando Y., Minami H., Saka H., Ando M., Sakai S., Shimokata K. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer. 1997;76(8):1067-1071.

   Not in our library10.1038/bjc.1997.509

2. 2.

   Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756.

   Not in our library10.1200/jco.1989.7.11.1748

3. 3.

   Chantler C., Garnett E. S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969;37(1):169-180.

   Not in our library

4. 4.

   Chatelut E., Canal P., Brunner V., Chevreau C., Pujol A., Boneu A., Roché H., Houin G., Bugat R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87(8):573-580.

   Not in our library10.1093/jnci/87.8.573

5. 5.

   Childs W. J., Nicholls E. J., Horwich A. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol. 1992;3(4):291-296.

   Not in our library10.1093/oxfordjournals.annonc.a058182

6. 6.

   Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.

   Not in our library10.1159/000180580

7. 7.

   Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984;44(11):5432-5438.

   Not in our library

8. 8.

   Fukuda M., Oka M., Soda H., Terashi K., Kawabata S., Nakatomi K., Takatani H., Tsurutani J., Tsukamoto K., Noguchi Y. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res. 1999;5(12):3963-3969.

   Not in our library

9. 9.

   Gehan E. A., George S. L. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970;54(4):225-235.

   Not in our library

10. 10.

    Gietema J. A., Veldhuis G. J., Guchelaar H. J., Willemse P. H., Uges D. R., Cats A., Boonstra H., van der Graaf W. T., Sleijfer D. T., de Vries E. G. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer. 1995;71(6):1302-1307.

    Not in our library10.1038/bjc.1995.252

11. 11.

    Hartmann A. E. Accuracy of creatinine results reported by participants in the CAP Chemistry Survey Program. Arch Pathol Lab Med. 1985;109(12):1068-1071.

    Not in our library

12. 12.

    Huitema A. D., Mathôt R. A., Tibben M. M., Schellens J. H., Rodenhuis S., Beijnen J. H. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther. 2000;67(6):621-630.

    Not in our library10.1067/mcp.2000.106827

13. 13.

    Jelliffe R. W., Iglesias T., Hurst A. K., Foo K. A., Rodriguez J. Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet. 1991;21(6):461-478.

    Not in our library10.2165/00003088-199121060-00006

14. 14.

    Jelliffe R. W. Letter: Creatinine clearance: bedside estimate. Ann Intern Med. 1973;79(4):604-605.

    Not in our library10.7326/0003-4819-79-4-604

15. 15.

    Jodrell D. I., Egorin M. J., Canetta R. M., Langenberg P., Goldbloom E. P., Burroughs J. N., Goodlow J. L., Tan S., Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520-528.

    Not in our library10.1200/jco.1992.10.4.520

16. 16.

    Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.

    Not in our library10.7326/0003-4819-130-6-199903160-00002

17. 17.

    Martin L., Chatelut E., Boneu A., Rostaing L., Roussilhes C., Caselles O., Canal P. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer. 1998;85(7):631-636.

    Not in our library

18. 18.

    Millward M. J., Webster L. K., Toner G. C., Bishop J. F., Rischin D., Stokes K. H., Johnston V. K., Hicks R. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute. Aust N Z J Med. 1996;26(3):372-379.

    Not in our library10.1111/j.1445-5994.1996.tb01925.x

19. 19.

    Newell D. R., Pearson A. D., Balmanno K., Price L., Wyllie R. A., Keir M., Calvert A. H., Lewis I. J., Pinkerton C. R., Stevens M. C. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol. 1993;11(12):2314-2323.

    Not in our library10.1200/jco.1993.11.12.2314

20. 20.

    O'Reilly S., Rowinsky E. K., Slichenmyer W., Donehower R. C., Forastiere A. A., Ettinger D. S., Chen T. L., Sartorius S., Grochow L. B. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol. 1996;14(12):3062-3073.

    Not in our library10.1200/jco.1996.14.12.3062

21. 21.

    Okamoto H., Nagatomo A., Kunitoh H., Kunikane H., Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol. 1998;42(4):307-312.

    Not in our library10.1007/s002800050822

22. 22.

    Peng B., Boddy A. V., Cole M., Pearson A. D., Chatelut E., Rubie H., Newell D. R. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer. 1995;31A(11):1804-1810.

    Not in our library10.1016/0959-8049(95)00382-s

23. 23.

    Perrone R. D., Madias N. E., Levey A. S. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933-1953.

    Not in our library

24. 24.

    Perrone R. D., Steinman T. I., Beck G. J., Skibinski C. I., Royal H. D., Lawlor M., Hunsicker L. G. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1990;16(3):224-235.

    Not in our library10.1016/s0272-6386(12)81022-5

25. 25.

    Pflüger K. H., Hahn M., Holz J. B., Schmidt L., Köhl P., Fritsch H. W., Jungclas H., Havemann K. Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol. 1993;31(5):350-356.

    Not in our library10.1007/bf00686147

26. 26.

    Reece P. A., Stafford I., Russell J., Khan M., Gill P. G. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5(2):304-309.

    Not in our library10.1200/jco.1987.5.2.304

27. 27.

    Salazar D. E., Corcoran G. B. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84(6):1053-1060.

    Not in our library10.1016/0002-9343(88)90310-5

28. 28.

    van Warmerdam L. J., Rodenhuis S., ten Bokkel Huinink W. W., Maes R. A., Beijnen J. H. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol. 1996;37(3):266-270.

    Not in our library10.1007/bf00688327

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.